(COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern Colorado frustrated. A Dexcom is responsible for monitoring ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset, but management are optimistic about rebuilding BME sales channel. DexCom's newest G7 CGM competes closely ...

DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users. Taylor Leamey wrote about all things wellness for CNET, specializing in ...

DexCom reported second quarter earnings and issued guidance after the market closed on Wednesday. The company reported adjusted EPS of 43 cents beating analyst estimates of 39 cents. Get access to the ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

Feb 13 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...